Loading clinical trials...

A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus | Clinical Trials | Clareo Health

TERMINATEDPHASE2

A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus

A Randomized, Double-blind, Parallel, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of Oral GW677954 Capsules (15 mg) in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus

NCT00437164•GlaxoSmithKline

View on ClinicalTrials.gov

Summary

Many drugs used for the treatment of Type 2 Diabetes Mellitus cause the body to retain water. This study will assess whether or not GW677954 causes the body to retain fluid.

Eligibility

Age

30 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have been diagnosed by a doctor with Type 2 Diabetes Mellitus at least 3 months before Screening
•Have a body mass index within range 25 to 40.0kg/m2 inclusive
•Females who meet above criteria must be physiologically incapable of becoming pregnant (ie., surgically sterilized, or post-menopausal per protocol definition)

Exclusion Criteria

•Significant weight loss or gain in the 3 months before screening
•Have used insulin to treat hyperglycemia within 3 months before screening
•Have a history of fluid retention
•Have uncontrolled high blood pressure
•Have liver disease
•Take loop diuretics (water pills), certain blood thinners, and/or St. Johns Wort. - Have or have had certain kinds of cancer

Locations (1)

GSK Investigational Site

Beverly Hills, California, United States

Key Dates

Start Date

September 1, 2006

Primary Completion Date

November 1, 2006

Completion Date

November 1, 2006

Last Updated

June 4, 2012

Enrollment

ACTUAL participants

Conditions

Type 2 Diabetes MellitusDiabetes Mellitus, Type 2

Interventions

Insulin

DRUG

Oral GW677954 Capsules (15 mg)

DRUG

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGNA

Achieving Routine Intervention and Screening for Emotional Health

NCT06887049

Type 2 Diabetes Mellitus (T2DM)Diabetes Distress

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 4, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Achieving Routine Intervention and Screening for Emotional Health

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus

Human Immunodeficiency Virus (HIV) Food Insecurities

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion